SOURCE: Atlan International Holdings Corp.

May 22, 2007 03:00 ET

Atlan International Holdings Corp. Signs Memorandum of Understanding With Pavilion of Parsippany to Develop Live In Facility for Alzheimer Patients

PRINCETON, NJ -- (MARKET WIRE) -- May 22, 2007 -- Atlan International Holdings Corp. (FRANKFURT: QV8) (PINKSHEETS: ATLI), a company which is a global development, marketing, sales and acquisition firm with subsidiaries that develop, design and market pharmaceuticals, biotechnology, bio-pharmaceuticals, alternative medicines & nutraceuticals, and alternative energy & processes, announced today that it has signed Memorandum of Understanding (MOU) with The Pavilion of Parsippany to develop live in facility for Alzheimer patients. Atlan intends on developing Centers in Europe and Asia as part of a global Alzheimer awareness program.

"Joining forces with Atlan increases our ability to negotiate better construction and expansion agreements around the country and abroad, taking advantage of the multi-tasking nature of today's business, and demonstrates our commitment to joint development," said Michael Puschak, Managing Director and Project Manager for The Pavilion.

The Pavilion retirement and assisted living facility for Alzheimer patients will begin an estimated $12 million construction this fall to address the needs of a growing group of Alzheimer's patients in New Jersey. Puschak says an increasing number of Alzheimer's cases are behind the expansion. The dedicated facility will allow residents to move about in a controlled and safe environment.

According to WebMD Medical News report of March 20, 2007 -- Alzheimer's disease is rising rapidly in America, now affecting at least 5.1 million and expected to hit 7.7 million by 2030; perhaps tripling to 16 million by 2050.Those figures, released today by the Alzheimer's Association, don't tell the whole story.

The new numbers also conceal a frightening statistic: An estimated 500,000 Americans under age 65 -- some as young as 30 -- suffer early-onset Alzheimer's disease.

The cause of death for Alzheimer's patients is often wrongly attributed to other diseases such patients may have, says Stephen McConnell, PhD, Vice President for public policy and advocacy at the Alzheimer's Association.

"This is not just a memory disease. It is a disease that kills you," McConnell tells WebMD. "What should really scare us is that you see a decline in cancer and heart disease deaths but a rapid increase in Alzheimer's disease. And the two are not unrelated. As we live longer, we are more susceptible to Alzheimer's."

About Atlan International Holdings Corp. (FRANKFURT: QV8) (PINKSHEETS: ATLI); Atlan is a global development, marketing, sales and acquisition firm with subsidiaries that develop, design and market pharmaceuticals, biotechnology, bio-pharmaceuticals, alternative medicines & nutraceutical, and alternative energy & processes. Atlan's international relationships and strengths allow it to offer products for co-development and to independently market & co-market multiple products.

Safe Harbor Statements under the Private Securities Litigation Reform Act of 1965: Those statements contained herein which are not historical are forward-looking statements, and as such, are subject to risks and uncertainties that could cause actual operating results to materially differ from those contained in the forward-looking statements. Such statements include, but are not limited to, certain delays that are beyond the company's control, with respect to market acceptance of new technologies, or product delays in the testing and evaluation of products, and other risks, as detailed in the company's periodic filings with the Securities and Exchange Commission.

Contact Information